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Purpose: Apolipoprotein A-I (ApoA-I) and apolipoprotein B-100 (ApoB-100) are amphipathic
proteins that are strong predictors of cardiovascular disease risk. The traceable calibration
of apolipoprotein assays is a persistent challenge, especially for ApoB-100, which cannot be
solubilized in purified form.
Experimental design: A simultaneous quantitation method for ApoA-I and ApoB-100 was
developed using tryptic digestion without predigestion reduction and alkylation, followed by
LC separation coupled with isotope dilution MS analysis. The accuracy of the method was
assured by selecting structurally exposed signature peptides, optimal choice of detergent, pro-
tein:enzyme ratio, and incubation time. Peptide calibrators were value assigned by isobaric
tagging isotope dilution MS amino acid analysis.
Results: Themethod reproducibility was validated in technical repeats of three serum samples,
giving 2–3% intraday CVs (N = 5) and <7% interday CVs (N = 21). The repeated analysis of
interlaboratory harmonization standards showed −1% difference for ApoA-I and −12% for
ApoB-100 relative to the assigned value. The applicability of the method was demonstrated by
repeated analysis of 24 patient samples with a wide range of total cholesterol and triglyceride
levels.
Conclusions and clinical relevance: The method is applicable for simultaneous analysis of
ApoA-I and ApoB-100 in patient samples, and for characterization of serum pool calibrators
for other analytical platforms.
Keywords:
Apolipoproteins / Cardiovascular system / Mass Spectrometry / LC-MS/MS / Quanti-
tation
 Additional supporting information may be found in the online version of this article atthe publisher’s web-site
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1 Introduction
Cardiovascular disease (CVD) is a progressive condition that
can lead to heart attack or stroke; two major causes of mortal-
ity throughout the world. Epidemiologic studies consistently
show strong correlation between plasma lipoprotein levels
and CVD risk [1]. Lipoproteins are relatively large endoge-
nous molecular assembles with unique size, density, and
lipid/protein composition. Lipoproteins, circulating in fast-
ing state, are commonly classified by their density into high,
low, intermediate, and very low density classes (HDL, LDL,
IDL, and vLDL) [2].
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Clinical Relevance
In the ongoing effort to improve cardiovascular risk
assessment and treatment strategies, apolipoprotein
(Apo) A-I and B-100 basedmetrics of plasma lipopro-
tein levels is gaining clinical acceptance. Currently,
clinical measurements of ApoA-I and ApoB-100 are
performed by immunoassays coupled with various
indirect detection techniques that require traceabil-
ity to purified or recombinant protein primary cali-
brators. The traceable calibration of apolipoprotein
immunoassays is a persistent challenge, especially
for ApoB-100, which cannot be solubilized in purified
form. The MS-based analytical approach is a poten-
tial alternative that allows quantification of ApoA-I
and ApoB-100 in biological matrices by proteolytic
digestion and selective quantification of protein-
specific tryptic peptides in the digestion mix. This
approach allows the use of external synthetic peptide
calibrators that are traceable to amino acid primary
reference standards. However, a major challenge of
the MS-based approach is the stoichiometric cleav-
age of the signature peptides from the apolipopro-
teins of interest. This work addresses the stoichio-
metric cleavage problem and demonstrates method
precision and accuracy that allows the application of
the method both for simultaneous analysis of ApoA-I
and ApoB-100 in patient samples, and for characteri-
zation of serumpools that can be used as apolipopro-
tein calibrators for other analytical platforms.
Inmost healthcare settings, routineCVDrisk assessments
include the fasting lipid profile, HDL-C and LDL-C, along
with total serum cholesterol (TC) and triglyceride (TG) lev-
els. Historically, the use of the standard lipid panel has led
to improved screening of high risk individuals. However, as
shown in a frequently cited study of 136 905 patients admitted
to 541 hospitals over a 6-year period, it was found that about
50% of the patients had HDL-C, LDL-C, and TG levels in a
range near normal cut-off values at the time of admission
[3]. Based on standardized TC and TG metrics of lipopro-
teins, numerous clinical guidelines and risk calculators were
developed that vary by geographical regions and ethnicity
[4, 5]; however, their application is often found confusing,
impractical, or underused in common individual patient care
settings [6].
In an effort to improve CVD risk assessment, apolipopro-
tein (apo) based metric of lipoproteins is gaining clinical ac-
ceptance [7]. Apos are responsible for the structural integrity
and function of lipoprotein particles, and are potentiallymore
directly linked to the underlying lipid metabolism irregular-
ities that lead to CVD in individual patients. The main apos
with established CVD risk correlation are Apolipoprotein A-I
(ApoA-I) and apolipoprotein B-100 (ApoB-100). As the main
functional proteins of lipid particles, ApoA-I and ApoB-100
provide a more accurate measure of HDL and LDL particle
levels than traditional TC and TG metrics.
Currently, approved clinical measurements of apos are
performed by immunoassays coupled with a variety of la-
beling and indirect detection techniques. The calibration of
immunoanalyzer platforms and kits is achieved in a hierar-
chical reference method system, by calibrating one affinity
assay with another using value assigned serum pools as cali-
brators. The value assignment of the ApoA-I calibrator pools
can be traced to a specific purified ApoA-I reference mate-
rial, but the ApoB-100 calibrator pools can be traced only to a
freshly prepared LDL density fraction pool [8, 9].
LC-MS/MS analysis of proteins is based on direct
molecule mass selective detection of protein specific prote-
olytic peptides (target or signature peptides) generated by
trypsin. The LC-MS/MS peak area of the native target peptide
is normalized with the simultaneously detected peak area of
an analogous stable isotope labeled internal standard (IS), al-
lowing the calculation of their peak area ratio (response ratio
or response factor). The calibration of the LC-MS/MS mea-
surement is performed by generating a response ratio versus
calibrator concentration curve. This approach has typically
been called isotope dilution MS (IDMS). Ideally, the calibra-
tor is a purified, recombinant protein with known molecular
weight, in dry powder form that can be accurately weighed.
However, such synthetic recombinant protein is not always
available. Even when it is available, it cannot be measured
out by weight because of uncontrollable water content, post-
translational modifications, or it cannot be solubilized from
a dried isolated state; as in the case of ApoB-100 [10].
An alternative way of addressing the calibration traceabil-
ity problem of apolipoproteins measurements is with the use
of protein specific, synthetic proteolytic peptide analogs as
external calibrators. The feasibility of the external peptide
calibration IDMS approach was demonstrated for the value
assignment of the purified ApoA-I primary standard (BCR-
CRM-393) [11], and is considered as amodel for a primary ref-
erencemethod procedure of apos [10]. The peptide calibration
approach for ApoB-100 has proven to be more challenging.
Because of its size (515 kDa) and physicochemical properties,
purified ApoB-100 forms aggregates that precipitate without
its phospholipid matrix [12]. Solubility problems during pro-
tein digestion can be mediated with predigestion reduction
and alkylation, high concentrations of various detergents or
organic solvents in the digestionmix, and overnight digestion
[13–17]. These steps are often followed by postdigestion clean-
ing steps, such as detergent precipitation [18], SPE, [19,20], or
antipeptide antibody capture [21]. However, these extensive
C© 2017 The Authors. PROTEOMICS – Clinical Applications published by WILEY-VCH Verlag GmbH & Co. KGaA www.clinical.proteomics-journal.com
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pre- and postdigestion treatment steps can contribute to unin-
tended peptide modifications, extended sample preparation
times, and cleavage product degradation [22].
In this study, we explored an approach that did not
use predigestion reduction/alkylation for the quantitation of
ApoA-I and ApoB-100. The key to our approach is the use of
target peptides that are rapidly cleaved by trypsin from sol-
vent exposed, loosely packed structural domains of lipidated
ApoA-I and ApoB-100, as embedded intoHDL and LDL parti-
cles. To evaluate this approach, we performed precision tests
by intraday and interday technical repeats on three serum
samples, and 24 patient samples with a wide range of TC and
TG levels. We also analyzed matrix-based reference reagents
(SP1-01 and SP3-08) that are currently accepted for standard-
ization by the World Health Organization (WHO). Based on
our results, we make a case for the use of external peptide
calibration as a feasible approach for value assignment of
ApoB-100 calibrators for other analytical platforms.
2 Materials and methods
2.1 Solvents and reagents
Unless specified, all reagents and solvents were purchased
from Thermo Fisher Scientific (Fair Lawn, NJ, USA).
Lyophilized Rapigest SF
R©
(RSF) detergent was purchased
from Waters Corporation (Milford, MA, USA). The RSF de-
tergent was resuspended to 0.6% g/g concentration using
500 mM Tris-HCl/1mM CaCl2, pH 8.5. The RSF working so-
lution was stored for maximum 30 days at 4◦C. Trypsin Gold
(MS-grade)was purchased fromPromegaCorporation (Madi-
son, WI, USA); a 1 mg/mL trypsin solution was prepared
fresh before use in 500 mM Tris-HCl/1mM CaCl2, pH 8.5.
2.2 Preparation and value assignment of synthetic
peptide stock solutions
Native and 13C/15N-labeled synthetic peptideswere purchased
in solid form from Midwest Bio-Tech (Fishers, IN). The in-
dividual peptide stock solutions were prepared with 0.1%
formic acid/water and nominal concentration of 50 pmol/L,
then distributed into 400 L aliquots and stored at −70C. A
frozen aliquot of each peptide stock solution was sent to Mid-
west Biotech for amino acid analysis. A second amino acid
analysis of each stock solution was performed in house by
four repeated measurements. The in-house method incorpo-
rated isobaric-tagging (iTRAQ, AB Sciex) and isotope dilu-
tion MS, using 15 NIST (U.S. National Institute of Standards
and Technology) certified native amino acid calibrators and
their isotope-labeled analogs [23]. The accuracy of concentra-
tions in the reconstituted native and IS stock solutions was
confirmed by experiments comparing native/IS area ratios
versus native/IS expected mole ratios (Table 1).
2.3 Preparation of calibration standards
The value assigned frozen peptide stock solutions were
thawed, mixed together, and diluted with 0.1% formic acid
using a Biomek FXp liquid handler system from Beckman
Coulter (Brea, CA, USA) for enhanced reproducibility. A se-
ries of working calibration standards were prepared, at nine
concentration levels between 60–60 000 nmol/L for ApoA-
I and 5–1300 nmol/L for ApoB-100, and spiked with the IS
solutionmix. Eachworking calibration standardmix also con-
tained 1 nmol/mL Glu-fibrinopeptide solution to reduce ad-
sorptive peptide loss. The calibration standard/IS mix series
was stored at 4C for a maximum of 4 weeks.
2.4 Preparation and storage of serum samples
Three fresh units of serum from anonymous donors (400
mL units) were purchased from Interstate Blood Bank (Mem-
phis, TN.). After arrival, each unit was immediately dis-
tributed into 0.5–1 mL aliquots, and stored at −80C until
use as quality control materials (QC1, QC2, and QC3). Fresh
residual serum aliquots from 24 deidentified patients were
provided by Health Diagnostic Laboratory Inc. (Richmond,
Table 1. Peptides chosen for ApoA-I and ApoB-100 quantitation
Protein Peptide MRM % Difference of amino
acid analysis methods
(in-house method versus
vendor method)
[Native/IS area
ratio]/[native/IS mole
ratio]
Native IS
ApoA-I AELQEGAR y6, y7, y8 0.0 +5.6 1.06
AHVDALR y4, y5 +7.4 +7.3 0.94
ApoB-100 ATGVLYDYVNK y5, y6, y7 +8.6 +6.6 1.07
LATALSLSNK y5, y6, y8 +5.2 +5.3 1.02
Concentrations of peptide stock solutions were determined by amino acid analysis using NIST traceable calibrators and based on value
assignment by the peptide vendor. As additional evidence of peptide concentration accuracy the match between Native/IS peak area ratio
versus expected mole ratios are shown.
C© 2017 The Authors. PROTEOMICS – Clinical Applications published by WILEY-VCH Verlag GmbH & Co. KGaA www.clinical.proteomics-journal.com
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VA); analyzed after storing in 4C refrigerator overnight. The
reference sera used for evaluating method bias were SP1-
01 (ApoA-I) and SP3-08 (ApoB-100). Both reference serum
standards were provided from the Lipid Standardization Pro-
gram at the Centers for Disease Control and Prevention (At-
lanta, GA). After thawing, the standards were distributed into
smaller aliquots and stored at −80C for interday repeat anal-
ysis. Two frozen secondary reference serum pools (blue and
white cap) were also received from Northwest Lipid Research
Laboratory (Seattle, WA) and stored at −80C until use.
2.5 Trypsin digestion using RSF detergent
To 10 L of sera, 990 L of 1× PBS, pH 8.5 was added in a
1.5 mL microcentrifuge tube (Eppendorf, USA). When men-
tioned, samples were reduced with 5mMdithiothreitol for 30
min at 60C, then alkylated with 10 mM 2-iodoacetamide for
60 min at 25C in the dark. The digestion was performed in
8-well 350 L PCR sample strips (FisherScientific, USA). To
each well containing 30 L of diluted serum, 5 L of labeled
IS peptide mix, 5 L 0.6% RSF, and 5 L of 1 mg/mL trypsin
was added followed with digestion at 37C for 3 h. To quench
the digestion and degrade the acid labile RSF detergent, 3
L of 0.5N HCl was added, followed by a 30-s mixing on a
benchtop vortexer at 200 rpm, and incubation for 1 h at 37C.
2.6 Trypsin digestion using sodium deoxycholate
detergent
A 4 L aliquot of each serum sample was diluted 50-fold
with addition of 50 mM ammonium bicarbonate, pH 8.0, IS
peptide mix, and 0.5% sodium deoxycholate (SDC; Sigma,
St. Louis, MO). To stop the digestion, 10 L 20% formic
acid was added precipitating the SDC. After centrifuging the
samples for 2 min at 1700 rpm, the supernatant was removed
manually for IDMS analysis.
2.7 LC-MS/MS analysis
All analyses were performed using a 6500 QTRAP (Sciex,
Framingham, MA) controlled by Analyst software (v1.6.2).
The Acquity UPLC system (Waters) was used with a 2.1 ×
100 mm column packed with HALO C18 stationary phase
(2.7 m particle size) flowing at 350 L/min. Solvents A and
B were 0.1% formic acid in 100% water and 0.1% formic acid
in 100% ACN. The 8-min gradient started at an A:B ratio of
98:2 and was held constant for 30 s. Over 5 min, the gradient
was increased to 80:20. The gradient was then increased to
5:95 over 1 min and then held constant for 30 s. Finally, the
column was reequilibrated to initial conditions over 1 min at
a flowrate of 600 L/min. The mass spectrometer was set to
operate in scheduled MRM. A 60 s window was scheduled
around the expected retention times with a target cycle time
of 0.6 min. The source temperature was 500C with a spray
voltage of 5 kV. The collision gas setting was set to “high.”
2.8 Calculation of protein concentrations from
peptide calibration curves
The LC-MS/MS peak areas weremeasured usingMultiQuant
(v3.0.2, AB Sciex). A separate (area ratio) versus (mole ratio)
calibration curve with 1/x weighing was generated for each
peptide MRM.
[Area ratio] =
[
Native peptide peak area
]
[
IS peptide peak area
]
= Slope ×
[
Mole of native peptide in standard
]
[
Mole of IS peptide in standard
]
+ Intercept (1)
The response ratios of the 100-fold diluted unknowns for
ApoA-I were between the second and fourth standards, and
for ApoB-100 between the fourth and seventh standards (first
being the highest standard).
Using the calibration curve slope and intercept for each
MRM, protein concentrations in the unknown samples were
determined by:
[Protein concentration]
= [Area ratio for unknown]−Intercept
Slope
× [Mole of IS peptide in unknown]
× 1[
Digested serum volume
] (2)
All calculated concentrations were exported into JMP (v11,
SAS, Cary, NC). The reported ApoA-I and ApoB-100 concen-
trations were calculated as the average of the concentrations
derived from corresponding MRMs (five MRMs for ApoA-I
and six MRMs for ApoB-100).
2.9 Other methods
The ApoB-100 ELISA kit was purchased from Abcam (Cam-
bridge, MA) and used according to the directions provided
by the manufacturer (Supporting Information). Cholesterol
and TG analysis was performed with an IDMS method, cali-
brated and validated using NIST-certified reference materials
(Supporting Information). To obtain HDL and LDL fractions
and to measure HDL-C and LDL-C concentration, samples
were fractionated by asymmetric flow field-flow fractionation
(AF4) [24]. Fiftymicroliters aliquot of serumwas injected into
an AF2000 system (Postnova Analytics, Germany) with PBS
C© 2017 The Authors. PROTEOMICS – Clinical Applications published by WILEY-VCH Verlag GmbH & Co. KGaA www.clinical.proteomics-journal.com
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buffer as the carrier fluid. HDL-C and LDL-C in the serum
samples were calculated by summing the measured choles-
terol content of the individual fractions from 6 to 18 nm and
18 to 30 nm, respectively. TC and TG of the serum fractions
were also measured by IDMS analysis without AF4 fraction-
ation. Non-HDL-C was calculated as (TC) − (HDL-C).
3 Results
3.1 Peptide screening
To find peptide candidates suitable for high-throughput sam-
ple analysis without reduction and alkylation steps, discov-
ery experiments were performed considering the entire se-
quence of ApoA-I and ApoB-100. Based on these discovery
experiments (data not shown), we generated an extended
list of rapidly releasable ApoB-100 and ApoA-I peptides. We
eliminated sequences with doubly charged molecular ions
>1200 m/z (instrument upper mass limit), and amino acid
residues prone to oxidation (M andW), reducing the number
of peptides to 32 for ApoB-100 and 13 for ApoA-I. Lipopro-
tein rich serum was fractionated by AF4 and fractions were
merged to obtain solutions of isolated HDL and LDL. Three
replicate aliquots of the HDL and LDL samples were digested
with RSF and SDC detergents. At each time point during a
24-h digestion (0.08, 0.25, 0.5, 1, 2, 4, 8 and 24 h), a 30 L
aliquot was analyzed by LC-MS/MS (Supporting Informa-
tion Figs. 1 and 2). The peak areas were normalized by the
maximum peak area found for each peptide in the entire
experiment (including SDC and RSF digestions). The nor-
malized peak areas versus the peptide sequence/position at
1 and 4 h are compared in Fig. 1A and B. As shown by the
1 h peak areas, the digestion rates were faster with SDC than
with RSF. However, after 8 h several peptides area counts
decreased with SDC, indicating their significant degradation
after cleavage.
3.2 Validation of maximum peptide cleavage
Based on stable and relatively highpeak area counts between 3
and 4 h, we selected four ApoA-I peptides and four ApoB-100
peptides and obtained both their native- and isotope-labeled
analogs. The digestion time course experiment was repeated
using diluted serum spiked with the labeled peptides. Us-
ing 0.6% RSF and 0.5% SDC, five replicate digestions were
prepared and analyzed over 24 h, mean area count profiles
are shown in Supporting Information Fig. 4. Of the labeled
peptides spiked into the digestion mix at the beginning of
the incubation, two showed stable peak areas for ApoA-I and
two for ApoB-100 with the RSF detergent, decreasing <5%
during the course of 24 h. With SDC, only one of the four
labeled peptides remained stable both for ApoA-I and ApoB-
100. The degradation of the ISs with SDC was also apparent
from the final area ratios versus digestion time curves (Fig. 2),
showing somewhat higher maximum area ratios with SDC
than with RSF. Therefore, at our chosen conditions, with-
out predigestion reduction and alkylation, RSF was found to
be a more suitable detergent than SDC. Based on cleavage
efficacy and stability, two ApoB-100 peptides, LATALSLSNK-
3395 and ATGVLYDYVNK-4077, and two ApoA-I peptides,
AELQEGAR-148 andAHVDALR-178, were selected for quan-
tification; using the native analogs as calibrators and their
labeled analogs as IS. After further experiments to check
ruggedness with variation of pH and temperature, a 3-h in-
cubation time was chosen. NontargetedMS/MS experiments
showed no signs of deamidation or missed cleavage products
around these sequences.
3.3 Validation of purity and concentration of peptide
calibrators
The purity of the frozen peptide stock solutions was first
checked with UPLC-UV analysis. One frozen aliquot of each
native and stable isotope labeled analog was sent to a com-
mercial laboratory for amino acid analysis (Table 1). These
initial value assignments were used to estimate the amount
of reagents necessary for in-house amino acid analysis [23].
The in-housemethod was quality controlled with three NIST-
certified peptides (2.7–4.2% CV range). The measurements
on the ApoA-I andApoB-100 peptides were performed in four
parallel reactions using iTRAQderivatization and LC-MS/MS
analysis. The peptide concentrations of the stock solutions
were calculated based on multiple amino acid data (Table 1).
Only the in-housemeasurements were used for calculation of
the calibration standards concentrations. The concentration
values received from the commercial laboratory matched our
in-house measurements with >90% accuracy (Table 1). As
an additional confirmation of the amino acid analysis accu-
racy, equal volumes of native- and isotope-labeled analogs
were combined and analyzed by the LC-MS/MS method. Af-
ter correction for the expected concentration, the mean peak
area response ratio and expected mole ratio matched with 1.0
± 0.04 accuracy for the ApoA-I peptides and 1.04 ± 0.03 for
the ApoB-100 peptides (Table 1).
3.4 Validation of reproducibility
The method reproducibility was assessed in three ways as
follows. (i) Three control sera (QC1, QC2, and QC3) were
digested and analyzed in 21 runs over a 60-day period (N = 5
each day) as shown in Fig. 3 (actual values shown in Support-
ing Information Table 1). The intraassay quintuplicate mea-
surements had 2–3% CVs. The interassay CVs, calculated
from the 21 intraassay means, were <7% both for ApoA-I
and ApoB-100. (ii) During the 21 method validation runs, we
also analyzed reference standards (N= 5 each day), SP1-01 for
ApoA-I and SP3-08 forApoB-100, giving 3.9 and 4.8%CV (cal-
culated from intraday mean values). (iii) Twenty-four serum
C© 2017 The Authors. PROTEOMICS – Clinical Applications published by WILEY-VCH Verlag GmbH & Co. KGaA www.clinical.proteomics-journal.com
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Figure 1. Digestion of an LDL size fraction for
ApoB-100 (A) and an HDL size fraction for
ApoA-I (B) monitoring 32 and 13 target pep-
tides, respectively. Figure shows the digestion
mix at 1 h (top) and 4 h (bottom). The full time-
course data during 24 h is presented in Sup-
porting Information Fig. 2.
Figure 2. Time-course experiment to confirm
maximum peptide cleavage using 0.6% RSF
and 0.5% SDC. Five replicate digestions were
performed for each time point with one LC-
MS/MS injection from each replicate. With
RSF detergent, maximum area ratios were
reached between 3–4 h and remained near
constant through 24 h. With SDC detergent,
the higher maximum area ratios were the re-
sult of labeled peptide degradation as shown
by the absolute native and labeled peptide ar-
eas in Supporting Information Fig. 4.
C© 2017 The Authors. PROTEOMICS – Clinical Applications published by WILEY-VCH Verlag GmbH & Co. KGaA www.clinical.proteomics-journal.com
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Figure 3. Characterization of three quality
control serum pools. Coefficients of varia-
tion for intraday measurements were <2–
3% (N = 5) and for mean interday mea-
surements were 7% (N = 21).
samples were measured by duplicate analysis on 3 days. The
concentration range of the samples was 81–290 mg/dL for
TC, 35–284 mg/dL for TG, 94–271 mg/dL for ApoA-I, and
41–143 mg/dL for ApoB-100. The average CV of the individ-
ual intraday duplicate measurements were 3.1% for TC, 4.0%
for TG, 2.2% for ApoA-I, and 3.8% ApoB-100. The average
interday CVs were 3.5, 6.5, 6.3, and 5.1%, respectively.
3.5 Validation of linearity and accuracy
Method linearity was tested with analysis of serum dilutions
1:200, 1:100, and 1:60 (Supporting Information Fig. 5). In
equivalent concentration of the unknown samples before
1:100 dilution, these dilutions represented a range of 0.5–
2.0 g/L for both ApoA-1 and ApoB-100. During the 60-day
method validation, the peptide calibration standard series
and IS solutions were prepared two times from the origi-
nal individual stock solutions, causing <2% change in the
measured mean of the three QC pools; in the range of the
method precision variability.
The absolute method bias was evaluated by comparison
of the mean concentrations measured on 21 days in the SP1-
01 and SP3-08 WHO standards with the assigned values. In
the SP1-01 standard, the measured mean ApoA-I concentra-
tion was 1.49 g/L, −1% bias relative to the assigned value of
1.5 g/L. In the SP3-08 standard, the mean ApoB-100 concen-
tration was 1.02 g/L with a −12% bias relative to the assigned
value of 1.16 g/L. To confirm that the bias for the ApoB-100
standard was not caused by avoiding the predigestion reduc-
tion and alkylation steps, we performed comparative analysis
and found that with and without reduction and alkylation
(n = 5 each) the bias was similar, −12 ± 0.72% and −10 ±
0.99%, respectively (Fig. 4).
In Supporting Information Fig. 6, the impact of potential
bias was examined based on the data from the analysis of
24 serum samples with a wide range of TC and TG values.
The between-MRM correlation slopes for the ApoA-I pep-
tides were 0.97–0.98 (R2 = 0.93–0.99), for ApoB-100 peptides
0.91–0.97 (R2 = 0.96–0.97). The between peptide correlations
for ApoA-I (AHVDALR/AELQEGAR) was 0.98 (R2 = 0.91)
and for ApoB-100 (LATALSNK/ATGLVYDYVNK) was 1.07
(R2 = 0.95). Three MRM transitions from each peptide were
used for calculation of the protein concentrations, except for
the ApoA-I peptide AHVDALR using only two transitions
because of an interference in the heavy labeled IS.
We also analyzed the SP3-08 standard using a commer-
cially available ApoB-100 ELISA kit with vendor provided cal-
ibration standards that were harmonized with another im-
munoassay reference standard (SP3-07, vendor information).
Figure 4. Examination of method bias by analysis of an
ApoB-100 harmonization standard. Five replicate digestions
were analyzed on 3 days (N= 15). From left to right, the con-
centration of the ApoB-100 reference standard was mea-
sured by using the RSF detergent with no reduction and
alkylation (CVs = 6%), RSF detergent with reduction and
alkylation (CV = 11%), and ApoB-100 ELISA assay (CV =
19%). Error bars represent SD of measurements.
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The ELISA assay agreedwith our IDMSmeasurements show-
ing similar −10 ± 1.9% bias relative to the assigned SP3-08
value (Fig. 4). An additional test of both linearity and accuracy
was the analysis of low and high secondary reference serum
pools (blue and white cap, Supporting Information Fig. 5)
fromNorthwest Lipid Research Laboratory (Seattle, WA). For
ApoA-I, we obtained 8 and 1% bias, and for ApoB-100 −11
and −10% bias, respectively (N = 5 repeats on the same day).
4 Discussion
4.1 Selection of target peptides and digestion
conditions
In general, finding suitable target peptides for quantification
of apolipoproteins is a challenging task because of the diffi-
culty presented by the significant differences between qua-
ternary structure of apolipoproteins in endogenous lipidated
and denatured purified states. These structural differences
also effect the solvent exposure of signature peptides and
their accessibility to proteolytic cleavage by trypsin. The ef-
ficiency and rate of cleavage of specific peptides can also be
very different in various digestion conditions. Therefore, the
first step of our peptide selection process was the examina-
tion of peptide cleavage rates and efficacies along the protein
sequence in the presence of RSF and SDC detergents. The
pattern of the relative peptide cleavage rates as a function of
ApoA-I and ApoB-100 sequence position can be compared
in Fig. 1. In general, the cleavage rates were more consis-
tent across the protein sequence with SDC than RSF. With
RSF, fast trypsin cleavage correlated with flexible structural
regions, in a pattern predicted bymolecular dynamicsmodels
ofHDL (ApoA-I) and LDL (ApoB-100) [2,25–27]. The stronger
correspondence of cleavage rates with structural features of
lipid bound ApoA-I and ApoB-100 suggests that RSF caused
less significant denaturation of the HDL and LDL structures
than SDC.
Based on cleavage and stability, we selected two peptides,
ATGVLYDYVNK-4077 and LATALSLSNK-3395 for quantifi-
cation (Fig. 2). According to the consensus model of LDL,
ApoB-100 has a pentapartite NH2-1-1-2-2-3-COOH
domain structure [26]. Coincidently, LATALSLSNK-3395 is
located on the 2 domain near the LDL receptor binding site
of ApoB-100, while ATGVLYDYVNK-4077 is near a sharp
loop turn of the 3 domain [26]; thus expected to be surface
exposed for fast trypsin cleavage. The cleavage rate patterns in
Fig. 1 also indicated the solvent exposure of the 1 domain,
which is folded and less attached to the phospholipid surface
in LDL.One of the peptides in this region, TEVIPPLIENR-950
was also rapidly cleaved, but the sequence contains a P955S
variant site (rs13306206) and was dismissed as a candidate
for quantification.
ApoA-I consists of ten amphipathic  helices [28]. During
the initial discovery experiments peptides from helix 2, 3, 5,
7, and 8 gave LC-MS/MS peaks with relatively low signal to
noise. The greatest difference between using SDC and RSF
detergents was seen for helix 10 peptides. In the presence of
RSF, the highest cleavage rates were observed around helix 6.
In view of current consensus models of discoidal and spher-
ical HDL, these findings are not surprising [2, 25, 29]. Helix
10 functions as the main anchor of ApoA-I in phospholipid
surface binding. Modeling evidence suggests strong inter-
molecular interactions between helices 5/5’, 2/8’, and 3/7’,
the main stabilizing forces in the antiparallel arrangement
of ApoA-I molecules in both discoidal and spherical HDL
[2, 25, 29]; Helix 5 is also recognized as the lecithin choles-
terol acyl transferase binding site [2]. The models also predict
relatively loose 4/6’ and 6/4’ helix/helix alignments on the
two sides of 5/5’ alignment. Coincidently, our selection pro-
cess led to target peptides from the flexible helix 6 region,
AELQEGAR-148 and AHVDALR-178, consistent with their
fast trypsin cleavage.
It is important to note that the observed cleavage rates
of the ApoA-I and ApoB-100 peptides were the result of our
digestion strategy without reduction and alkylation. Other re-
search groups chose to use predigestion reduction and alky-
lation steps and observed different cleavage rate patterns,
therefore, they arrived to a different set of signature pep-
tides for ApoA-I and ApoB-100 quantification [13–16, 18, 21].
In general, apolipoprotein surface exposed regions occur be-
cause of proline and glycine rich loop regions. Because the
RSF detergent caused only partial denaturation of the protein
structures, our selected signature peptides are consistent with
the native lipidated apolipoprotein structures. Coincidentally,
polar proline containing peptides often elute in faster and
sharper peaks and at lower organic eluent content on re-
verse phase columns. They also ionize well in the ESI LC-MS
interface. Therefore, our digestion strategy and the LC-MS
detection technique naturally led us to the selection of short,
polar ApoA-I and ApoB-100 signature peptides.
We chose RSF detergent for two main reasons. First, the
observation that ApoA-I and ApoB-100maintained their lipid
bound tertiary structure in the presence of RSF was thought
to be an advantage by improving consistent exposure of the
selected target peptides and resulting in more reproducible
digestion rates and cleavage recovery. Second, RSF allowed
a simpler sample preparation workflow that was more feasi-
ble for automation. RSF by design is an acid-labile detergent
that can be degraded by simple addition of acid. Although the
time course experiments showed that RSF and SDC worked
with similar digestion efficacy, the acidification after diges-
tion with SDC generated a significant amount of precipitate
that was difficult to remove in an automated fashion.
The digestion efficiency was also determined by the
trypsin:protein ratio, 5 g trypsin for 18–25 g protein in 0.3
L serum (assuming 60–80 g/L of protein in a typical human
serum sample and digesting 30L of 100× diluted serum). In
general, we found that in various apolipoprotein studies using
a high amount of trypsin is very common (3–10 g/sample)
[18, 21]. In our method, using 1:4 to 1:5 trypsin:protein ra-
tio and relatively small volume of serum also allowed the
C© 2017 The Authors. PROTEOMICS – Clinical Applications published by WILEY-VCH Verlag GmbH & Co. KGaA www.clinical.proteomics-journal.com
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elimination of common pre- and postdigestion steps found
in traditional proteomic workflows (i.e., reduction, alkylation,
extraction), shortened the sample processing time, and led to
significant savings by not using other reagents and consum-
ables.
Altogether, the selection of rapidly cleaved target peptides,
small amount of serum (0.3 L), high trypsin:protein ratio al-
lowed a short sample preparation time of 4 h. Because there
was less time for cleavage product and IS peptide degrada-
tion, avoiding the predigestion alkylation step did not affect
accuracy and even enhanced the method precision.
In comparison to other reported IDMS methods, our di-
gestion and peptide calibration based approach has the dis-
advantage of being limited to the simultaneous analysis of
only ApoA-I and ApoB-100. This is mainly because the steep
criteria of the peptide calibration based quantification. The
calculation of accurate protein concentrations based on the
measured cleavage product concentration is possible only if
the digestion method is optimized to the maximum cleav-
age of the target peptides from the protein; approaching sto-
ichiometric cleavage efficiency as much as possible. With
increasing the number of proteins and corresponding pep-
tide targets, the level of difficulty for meeting this criteria
increases substantially. Therefore, we concede that with the
peptide-based calibration approach the level of multiplexing
ismore limited thanwith protein-based calibration, where the
bias from less than stoichiometric cleavage is automatically
corrected by the protein calibration curve. In our laboratory,
we use the peptide-calibrated IDMS approach only for ApoA-
I and ApoB-100. We also used this method to characterize
calibrator pools for other platforms such as on-line trypsin
digestion coupled LC-MS/MS where we apply protein cali-
bration and higher level of multiplexing [30].
4.2 Peptide based IDMS method accuracy
The absolute accuracy and precision of the ApoA-I and ApoB-
100 serumconcentrationmeasurementwas assuredby taking
multiple provisions. First, we obtained evidence of complete
peptide cleavage, that is, confirmation of limit peptide behav-
ior [31, 32], by showing that the native/IS response ratios re-
mained constant while IS signal intensities remained stable.
Second, extra steps were taken for the value assignment of the
peptide stock solutions by an amino acid analysismethodwith
enhanced specificity and reproducibility with NIST-certified
amino acid standards. Third, the peptide calibration series
was prepared using a carefully volume calibrated liquid han-
dler. Fourth, we usedmatrix-matched calibration tominimize
LC-MS/MS analysis variability, that is, the peptide calibration
standard series was incubated at the same time with the pro-
tein samples in the presence of the same reagent mix. Fifth,
to further minimize matrix effects, we diluted the serum
samples 100-fold, the maximum fold dilution that still al-
lowed sensitive LC-MS/MS detection. Sixth, the average of
multiple MS fragment ions was used for each concentration
determination. Seventh, the average of two peptide concen-
trations was used for the calculation of the protein concen-
trations. Eighth, three quality controls were used to monitor
method reproducibility, all three resulting in<3% intraassay
CVs and <7% interassay CVs.
Based on the average of multiple measurements on
21 days, our method compared well (−1% bias) with the
ApoA-I WHO reference standard (SP1-01). For the ApoB-100
WHO standard (SP3-08), our method showed a −12% bias.
We note that the value assignment of these reference stan-
dards was made around 1990, with the best quality of tech-
nologies available at that time. The value assignment of the
SP1-01 standard was performed by RIA using a primary pu-
rified reference standard (BCR-CRM-393), value assigned by
amino acid analysis,[8] and later byHPLC-coupled IDMS [11].
The value assignment of the SP3-08 standard was performed
by immunonephelometry with purified LDL used as an apoB-
100 calibrator, which was measured by an SDS-Lowry proce-
dure calibrated with purified BSA [9]. Therefore, the ApoB-
100 value assignment of SP3-08 was performed without a
direct primary measurement procedure or primary reference
material [10]. There is still noprimary referencematerial avail-
able for ApoB-100 because purified protein materials that are
commutable have not yet been produced. It also should be
noted that these reference materials were always intended to
be an interim solution until more accurately value-assigned
primary reference materials and an absolute accuracy-based
primary reference measurement procedure is developed [10].
4.3 Correlation of lipid levels with ApoB-100 and
ApoA-I levels
In spite of their potential as strong risk factors, apo analysis
has not been generally translated from research to regular
diagnostic use for CVD risk assessment; and is only consid-
ered as an advanced test. The current clinical guidelines still
advocate the use of lipid level based measures such as non-
HDL-C (non-HDL-C = TC − HDL-C), which can be readily
implemented in clinical settings without additional cost. The
correlation of non-HDL-C with ApoB-100 is usually found
0.8–0.85 [33–35]. However, the general correlation of calcu-
lated lipid measures with ApoB-100 levels may not result in
similar concordance with risk. In patient groups with wide
range of non-HDL-C levels (147-213 nmol/L), risk classifica-
tion based on non-HDL-C and ApoB-100 levels agreed in less
than 50% of patients [35]. Our analysis of 24 patient samples
with wide range of lipid profiles also showed correlation of
0.8 between non-HDL-C and ApoB-100, but only for sam-
ples with<145mg/dL non-HDL-C; including all samples the
correlation was only 0.60 (Fig. 5A).
Another advocated lipid-based measure is the non-HDL-
C/HDL-C ratio [33–35]. As with previous studies, we also
found similar correlation of 0.89 between the non-HDL-
C/HDL-C and ApoB-100/ApoA-I ratios (Fig. 5B). At the same
time, HDL-C versus ApoA-I (Fig. 5C) and LDL-C versus
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Figure 5. Correlation between cholesterol and
apolipoprotein concentrations for 24 serum samples.
(A) Non-HDL-C versus ApoB-100; (B) non-HDL-C/HDL-C
versus ApoB-100/ApoA-I; (C) HDL-C versus ApoA-I; (D)
LDL-C versus ApoB-100.
ApoB-100 (Fig. 5D) correlations were relatively low, 0.66 and
0.40, respectively, indicating lack of concordance with under-
lying metabolic abnormalities.
5 Conclusions
We have developed a high throughput, absolute protein
quantification IDMS work flow for the analysis of ApoA-I
and ApoB-100 in serum that meets the accuracy and repro-
ducibility requirements of clinical laboratory guidelines. To
achieve method accuracy and precision, we followed estab-
lished IDMS guidelines [36] stressing the importance of com-
plete peptide cleavage, validation of precision based on mul-
tiple quality control serum samples, matrix-matched peptide
calibration, and NIST traceable value assignment of the pep-
tide calibrators. An additional important outcome of thiswork
is the evaluation of bias for a peptide calibration based IDMS
method, based on the analysis of harmonization standards
(serum pools) that are currently recognized as the universal
reference materials for ApoA-I and ApoB-100 immunoassay
measurements. In the IDMS application presented here, us-
ing peptide calibrators and following IDMS procedure guide-
lines, the bias for ApoA-I (SP1-01 traceable to purified ApoA-I
primary referencematerial) was−1%. For ApoB-100 (SP3-08,
for which there is no purified primary reference material),
the IDMS approach yielded a −12% bias (as compared to
the value assignment by radial immunoassay, calibrated with
materials that were value assigned by SDS-Lowery). A −12%
bias is high by clinical laboratory standards and needs fur-
ther examination. For example, the assumption that in the
LDL density faction, which was used as a “pseudo-primary
calibrator,” the only protein present was ApoB-100 should
be reexamined, by using modern techniques that were not
available in 1990 when the SP3-08 standard was prepared [9].
In order for IDMS measurements of ApoA-I and ApoB-
100 to be applicable to clinical decision making or assess-
ment of CVD risk, it is becoming increasingly important to
place all measurements on a common accuracy base with
clinical immunoassays. There is currently no broad consen-
sus on the best way to implement this goal. One strategy
is to correct IDMS measurements to match the value of the
old ApoA-I and ApoB-100 immunoassay harmonization stan-
dards. For ApoB-100 specifically, it should be recognized that
the value assignment of the immunoassay harmonization
standard was made without an absolute accuracy-based ref-
erence measurement procedure and without a primary ref-
erence material [10]. Our work using the peptide calibration
based IDMS approach supports the notion that the uncer-
tainties about the 100% digestion efficacy are outweighed
by the systematic and stoichiometric traceability to amino
acid standards. As research continues to identify the roles of
apolipoprotein concentrations, particle size and particle num-
ber in CVD risk assessment, the need for accuracy-based ref-
erencematerials and referencemeasurement procedures will
surely grow. IDMS methods calibrated with accurately trace-
able peptide calibrators should play a role in these efforts.
The findings and conclusions in this report are those of the
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Cholesterol and triglyceride analysis. A direct LC-MS/MS method was developed for analysis 
of cholesterol and triglyceride in AF4 fractions and diluted human serum [Gardner et. al., in preparation].  
The calibration standard mix was prepared in isopropanol.  Total cholesterol was quantified as the sum of 
free cholesterol and cholesteryl esters, using free cholesterol and cholesteryl palmitate as calibrator, 
respectively. Total triglycerides were measured using triolein, tripalmitin, and trilinolein in a ratio of 
3.0:1.8:1 by weight. Internal standard (IS) mix was prepared in ethanol, containing 0.033 mg/dL d7-
cholesterol (for FC quantitation), 0.098 mg/dL cholesteryl-d7-palmitate (for CE quantitation), and 0.125 
mg/dL d98-tripalmitin (for TG quantitation). 50µL aliquots were transferred from serum samples diluted 
1:100 with phosphate buffered saline (PBS) into a 96-well plate.  The protein-precipitation/extraction, by 
the addition of 0.2 mL IS/ethanol mix, was followed by evaporation and reconstitution in 100 µL nonane.  
The plate was covered with a heat-sealing foil mat for analysis by UHPLC-MS/MS.  The analysis method 
used normal phase liquid chromatography separation and in-source collision-induced dissociation (CID) 
coupled with tandem mass spectrometry detection.  The UHPLC system was a UHPLC-SA (Spark-
Holland, Emmen, Netherlands).  The mass spectrometer was a Sciex 4000 QTrap (AB Sciex, Framingham, 
MA). From each sample, 2µL is injected (full loop).  The column was a Luna HILIC 3µm, 2x50mm 
(Phenomenex, Torrance, CA).  Mobile phase A was hexanes with 0.1% isopropanol.  Mobile phase B was 
50:45:5 hexanes:ethanol:methanol.  The mobile phase flow rate was 600 µL / min with gradient elution.  
The gradient started at 0% B, holding for 0.5 minute, then to 15% B over 0.5 minute, holding for 0.5 
minute, returning to 0% B over 0.1 minute, holding 0% B for 1.9 minutes.  The Heated Nebulizer (APCI) 
source is installed.  The source conditions for all time periods in the method are:  Curtain Gas = 10 psi 
nitrogen, Nebulizer Current = 4µA, Temperature = 325°C, Gas 1 = 70 psi nitrogen, CAD = “Medium”.  
MRM conditions are given in Table S2. The free cholesterol and cholesteryl esters eluted in two separate 
chromatographic peaks but in the same m/z MRM trace, while all the triglycerides eluted in one single 
peak in the same m/z MRM trace.  The total cholesterol concentrations in mg/dL were calculated as a sum 
  
of the measured free cholesterol and the free-cholesterol-equivalent of all cholesteryl esters.  Triglyceride 
concentrations were calculated in mg/dL triolein-equivalent concentration. 
ELISA assay. The calibration series was prepared from the lyophilized purified human Apo B 
standard provided by the vendor (Abcam, Cambridge, MA). All samples including the calibration curve 
was analyzed in duplicates. After allowing the capture and detector antibodies to bind the ApoB-100 in 
the samples, the antibody-ApoB-100 complex was immobilized on the anti-tag antibody coated wells. The 
wells were washed to be remove any unbound ApoB-100. 3,3',5,5'-tetramethylbenzidine (TMB) substrate 
is used to stain the antibody complex. The reaction was completed by adding Stop Solution. The reaction 
color changed from blue to yellow. The intensity was measured using a spectrophotometer at 450 nm. The 
concentration of Apo B is proportional to the color produced after the reaction is completed. 
Asymmetric Flow Field-Flow Fractionation. Asymmetric flow field-flow fractionation (AF4) is 
based on the fundamental nature of laminar flow. A liquid medium passes through a thin channel which 
causes it to adopt a parabolic velocity profile across the height of the channel, with stream velocities faster 
at the center of the channel and slower near the walls.  When serum samples are injected into this stream, 
contained particles are subjected to a second, perpendicular field created by withdrawal of carrier fluid 
through a semipermeable membrane that drives them toward the accumulation wall, where they 
experience slower flow rates.  Once they are concentrated at the accumulation wall, particle species begin 
to diffuse up away from the accumulation wall via Brownian motion into higher velocity flow regimes, 
with frequency and magnitude according to their intrinsic diffusion coefficient and Stokes diameter. 
Differential retention is caused by the different average height achieved by particles of different sizes, 
with smaller particles having a higher average height which results in eluting them faster. The AF4 
separation requires no filtration or other sample pretreatment and is achieved by gentle fluid dynamics; 
both of these elements minimize the risk of introducing composition artifacts during separation.   
 
 
  
Figure S1. Full time-course digestion of LDL for ApoB-100 monitored based on 32 target peptides 
sampling the digestion mix at 0.08, 0.25, 0.5 1, 2, 4, 8 and 24 h. Curves were normalized to the maximum 
peak area for each peptide during the experiment. 
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Figure S2. Full time-course digestion of HDL for ApoA-I monitored based on 13 target peptides sampling 
the digestion mix at 0.08, 0.25, 0.5 1, 2, 4, 8 and 24 h. Curves were normalized to the maximum peak area 
for each peptide during the experiment. 
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Figure S3. Correlation of lipid parameters to apolipoprotein concentrations for 25 serum samples: A) 
Non-HDL-C/HDL-C vs. ApoB-100/ApoA-I; B) Non-HDL-C  LDL-C (red) and HDL-C (blue) vs. ApoA-
I and ApoB-100 (marker size by ApoA-I/ApoB-100 ratios). (colors blue-grey-red by low-medium-high 
ApoA-I/ApoB-100 ratios). Samples were stratified into Low and High total cholesterol groups (81-210 
mg/dL and 210-290 mg/dL) and total triglyceride groups (35-145 mg/dL and 145-284 ng/dL).  
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Figure S4:  Time course experimental data for the quantitation peptides used for area ratio plots in Figure 
2.   
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Table S1:  Raw data values for Figure 3.   
 
 
P
ro
te
in
Sa
m
p
le
 
D
at
e
 C
o
n
ce
n
tr
at
io
n
 (
g/
L)
P
ro
te
in
Sa
m
p
le
 
D
at
e
 C
o
n
ce
n
tr
at
io
n
 (
g/
L)
P
ro
te
in
Sa
m
p
le
 
D
at
e
 C
o
n
ce
n
tr
at
io
n
 (
g/
L)
A
P
O
A
1
Q
C
1
20
15
_1
00
7
1.
18
A
P
O
A
1
Q
C
2
20
15
_1
00
7
1.
25
A
P
O
A
1
Q
C
3
20
15
_1
00
7
1.
37
A
P
O
A
1
Q
C
1
20
15
_1
01
6
1.
13
A
P
O
A
1
Q
C
2
20
15
_1
01
6
1.
33
A
P
O
A
1
Q
C
3
20
15
_1
01
6
1.
50
A
P
O
A
1
Q
C
1
20
15
_1
02
1
1.
22
A
P
O
A
1
Q
C
2
20
15
_1
02
1
1.
28
A
P
O
A
1
Q
C
3
20
15
_1
02
1
1.
49
A
P
O
A
1
Q
C
1
20
15
_1
02
3
1.
04
A
P
O
A
1
Q
C
2
20
15
_1
02
3
1.
15
A
P
O
A
1
Q
C
3
20
15
_1
02
3
1.
27
A
P
O
A
1
Q
C
1
20
15
_1
02
7
0.
97
A
P
O
A
1
Q
C
2
20
15
_1
02
7
1.
18
A
P
O
A
1
Q
C
3
20
15
_1
02
7
1.
18
A
P
O
A
1
Q
C
1
20
15
_1
10
2
1.
06
A
P
O
A
1
Q
C
2
20
15
_1
10
2
1.
34
A
P
O
A
1
Q
C
3
20
15
_1
10
2
1.
29
A
P
O
A
1
Q
C
1
20
15
_1
10
6
1.
01
A
P
O
A
1
Q
C
2
20
15
_1
10
6
1.
21
A
P
O
A
1
Q
C
3
20
15
_1
10
6
1.
26
A
P
O
A
1
Q
C
1
20
15
_1
10
9
0.
97
A
P
O
A
1
Q
C
2
20
15
_1
10
9
1.
14
A
P
O
A
1
Q
C
3
20
15
_1
10
9
1.
25
A
P
O
A
1
Q
C
1
20
15
_1
11
2
1.
15
A
P
O
A
1
Q
C
2
20
15
_1
11
2
1.
37
A
P
O
A
1
Q
C
3
20
15
_1
11
2
1.
45
A
P
O
A
1
Q
C
1
20
15
_1
11
6
1.
09
A
P
O
A
1
Q
C
2
20
15
_1
11
6
1.
35
A
P
O
A
1
Q
C
3
20
15
_1
11
6
1.
41
A
P
O
A
1
Q
C
1
20
15
_1
11
8
1.
10
A
P
O
A
1
Q
C
2
20
15
_1
11
8
1.
42
A
P
O
A
1
Q
C
3
20
15
_1
11
8
1.
39
A
P
O
A
1
Q
C
1
20
15
_1
11
9
1.
04
A
P
O
A
1
Q
C
2
20
15
_1
11
9
1.
25
A
P
O
A
1
Q
C
3
20
15
_1
11
9
1.
33
A
P
O
A
1
Q
C
1
20
15
_1
12
3
1.
07
A
P
O
A
1
Q
C
2
20
15
_1
12
3
1.
24
A
P
O
A
1
Q
C
3
20
15
_1
12
3
1.
30
A
P
O
A
1
Q
C
1
20
15
_1
20
1
1.
10
A
P
O
A
1
Q
C
2
20
15
_1
20
1
1.
19
A
P
O
A
1
Q
C
3
20
15
_1
20
1
1.
41
A
P
O
A
1
Q
C
1
20
15
_1
20
8
0.
93
A
P
O
A
1
Q
C
2
20
15
_1
20
8
1.
16
A
P
O
A
1
Q
C
3
20
15
_1
20
8
1.
40
A
P
O
A
1
Q
C
1
20
15
_1
21
6
1.
10
A
P
O
A
1
Q
C
2
20
15
_1
21
6
1.
33
A
P
O
A
1
Q
C
3
20
15
_1
21
6
1.
44
A
P
O
A
1
Q
C
1
20
15
_1
21
8
1.
11
A
P
O
A
1
Q
C
2
20
15
_1
21
8
1.
29
A
P
O
A
1
Q
C
3
20
15
_1
21
8
1.
40
A
P
O
A
1
Q
C
1
20
15
_1
22
1
1.
06
A
P
O
A
1
Q
C
2
20
15
_1
22
1
1.
27
A
P
O
A
1
Q
C
3
20
15
_1
22
1
1.
38
A
P
O
A
1
Q
C
1
20
15
_1
22
2
1.
10
A
P
O
A
1
Q
C
2
20
15
_1
22
2
1.
37
A
P
O
A
1
Q
C
3
20
15
_1
22
2
1.
35
A
P
O
A
1
Q
C
1
20
15
_1
22
3
1.
04
A
P
O
A
1
Q
C
2
20
15
_1
22
3
1.
29
A
P
O
A
1
Q
C
3
20
15
_1
22
3
1.
37
A
P
O
A
1
Q
C
1
20
15
_1
23
1
1.
09
A
P
O
A
1
Q
C
2
20
15
_1
23
1
1.
37
A
P
O
A
1
Q
C
3
20
15
_1
23
1
1.
34
A
V
G
1.
07
A
V
G
1.
27
A
V
G
1.
36
SD
0.
07
SD
0.
08
SD
0.
08
C
V
6.
45
C
V
6.
46
C
V
5.
98
P
ro
te
in
Sa
m
p
le
 
D
at
e
 C
o
n
ce
n
tr
at
io
n
 (
g/
L)
P
ro
te
in
Sa
m
p
le
 
D
at
e
 C
o
n
ce
n
tr
at
io
n
 (
g/
L)
P
ro
te
in
Sa
m
p
le
 
D
at
e
 C
o
n
ce
n
tr
at
io
n
 (
g/
L)
A
P
O
B
Q
C
1
20
15
_1
00
7
0.
82
A
P
O
B
Q
C
2
20
15
_1
00
7
0.
47
A
P
O
B
Q
C
3
20
15
_1
00
7
0.
68
A
P
O
B
Q
C
1
20
15
_1
01
6
0.
82
A
P
O
B
Q
C
2
20
15
_1
01
6
0.
51
A
P
O
B
Q
C
3
20
15
_1
01
6
0.
80
A
P
O
B
Q
C
1
20
15
_1
02
1
0.
84
A
P
O
B
Q
C
2
20
15
_1
02
1
0.
47
A
P
O
B
Q
C
3
20
15
_1
02
1
0.
75
A
P
O
B
Q
C
1
20
15
_1
02
3
0.
73
A
P
O
B
Q
C
2
20
15
_1
02
3
0.
45
A
P
O
B
Q
C
3
20
15
_1
02
3
0.
69
A
P
O
B
Q
C
1
20
15
_1
02
7
0.
78
A
P
O
B
Q
C
2
20
15
_1
02
7
0.
51
A
P
O
B
Q
C
3
20
15
_1
02
7
0.
69
A
P
O
B
Q
C
1
20
15
_1
10
2
0.
79
A
P
O
B
Q
C
2
20
15
_1
10
2
0.
54
A
P
O
B
Q
C
3
20
15
_1
10
2
0.
71
A
P
O
B
Q
C
1
20
15
_1
10
6
0.
75
A
P
O
B
Q
C
2
20
15
_1
10
6
0.
49
A
P
O
B
Q
C
3
20
15
_1
10
6
0.
70
A
P
O
B
Q
C
1
20
15
_1
10
9
0.
79
A
P
O
B
Q
C
2
20
15
_1
10
9
0.
48
A
P
O
B
Q
C
3
20
15
_1
10
9
0.
69
A
P
O
B
Q
C
1
20
15
_1
11
2
0.
74
A
P
O
B
Q
C
2
20
15
_1
11
2
0.
49
A
P
O
B
Q
C
3
20
15
_1
11
2
0.
70
A
P
O
B
Q
C
1
20
15
_1
11
6
0.
78
A
P
O
B
Q
C
2
20
15
_1
11
6
0.
53
A
P
O
B
Q
C
3
20
15
_1
11
6
0.
74
A
P
O
B
Q
C
1
20
15
_1
11
8
0.
79
A
P
O
B
Q
C
2
20
15
_1
11
8
0.
56
A
P
O
B
Q
C
3
20
15
_1
11
8
0.
71
A
P
O
B
Q
C
1
20
15
_1
11
9
0.
80
A
P
O
B
Q
C
2
20
15
_1
11
9
0.
51
A
P
O
B
Q
C
3
20
15
_1
11
9
0.
78
A
P
O
B
Q
C
1
20
15
_1
12
3
0.
84
A
P
O
B
Q
C
2
20
15
_1
12
3
0.
50
A
P
O
B
Q
C
3
20
15
_1
12
3
0.
77
A
P
O
B
Q
C
1
20
15
_1
20
1
0.
80
A
P
O
B
Q
C
2
20
15
_1
20
1
0.
48
A
P
O
B
Q
C
3
20
15
_1
20
1
0.
75
A
P
O
B
Q
C
1
20
15
_1
20
8
0.
82
A
P
O
B
Q
C
2
20
15
_1
20
8
0.
52
A
P
O
B
Q
C
3
20
15
_1
20
8
0.
80
A
P
O
B
Q
C
1
20
15
_1
21
6
0.
77
A
P
O
B
Q
C
2
20
15
_1
21
6
0.
54
A
P
O
B
Q
C
3
20
15
_1
21
6
0.
80
A
P
O
B
Q
C
1
20
15
_1
21
8
0.
76
A
P
O
B
Q
C
2
20
15
_1
21
8
0.
49
A
P
O
B
Q
C
3
20
15
_1
21
8
0.
72
A
P
O
B
Q
C
1
20
15
_1
22
1
0.
77
A
P
O
B
Q
C
2
20
15
_1
22
1
0.
52
A
P
O
B
Q
C
3
20
15
_1
22
1
0.
76
A
P
O
B
Q
C
1
20
15
_1
22
2
0.
80
A
P
O
B
Q
C
2
20
15
_1
22
2
0.
54
A
P
O
B
Q
C
3
20
15
_1
22
2
0.
75
A
P
O
B
Q
C
1
20
15
_1
22
3
0.
83
A
P
O
B
Q
C
2
20
15
_1
22
3
0.
54
A
P
O
B
Q
C
3
20
15
_1
22
3
0.
81
A
P
O
B
Q
C
1
20
15
_1
23
1
0.
81
A
P
O
B
Q
C
2
20
15
_1
23
1
0.
55
A
P
O
B
Q
C
3
20
15
_1
23
1
0.
74
A
V
G
0.
79
A
V
G
0.
51
A
V
G
0.
74
SD
0.
03
SD
0.
03
SD
0.
04
C
V
3.
97
C
V
5.
87
C
V
5.
63
  
Supplementary Figure S5:  Linearity of method shown for sample dilutions 1:200,1:100 and 1:60.  The 
method brackets the reference ranges for ApoA-1 (a) and ApoB-100 (b).  Secondary reference materials 
were also analyzed (c,d) for testing method accuracy.  ApoA-I accepted values ranged from 1.1-1.6 g/L.  
ApoB-100 accepted values ranged from 0.7-1.7 g/L.      
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Supplementary Figure S6:  Validation data examining peptide bias for ApoA-I and ApoB-100.  For 
ApoA1, two transitions were chosen for the peptides AELQEGAR (a) and AHVDALR (b).  The peptide 
average has also been displayed (c).  Data for ApoB-100 is displayed in the same manner for peptides 
ATGVLYDYVNK (d), LATALSLSNK (e) and the peptide average (f).   
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